SEC Form 4
REGENXBIO Inc. (RGNX) insider trading
In the 12 months to Nov 4, 2026, one RGNX insider reported open-market sales of $940.0K across 4 filings; one director bought $949.4K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $940.0K
- 4 filings · 1 insider
- Open-market purchases
- $949.4K
- 1 filing · Gregory Austin Ciongoli, Director
- Pre-arranged sales (10b5-1)
- 3 of 4
- $251.2K of $940.0K sold (27%)
Who traded RGNX, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
RGNX daily close from Nov 4, 2025 to Nov 4, 2026, between $5.65 and $15.98, last $7.71. 4 sale and 1 purchase filings by 2 insiders, marked at their filing dates. Gregory Austin Ciongoli, Director: bought $949.4K across 1 filing, first filed Aug 27, 2026, last Aug 27, 2026. Steve Pakola, Chief Medical Officer: sold $940.0K across 4 filings, first filed Mar 12, 2026, last Jul 6, 2026.
Largest mark · tap a row for others
Gregory Austin Ciongoli · Director
Purchase $949,381
102,603 shares at $9.25 avg
Filed Aug 27, 2026 · traded Aug 26
Close on filing date $9.37
Gregory Austin Ciongoli · Director
Director
$949.4K boughtSteve Pakola · Chief Medical Officer
Chief Medical Officer
$940.0K soldOpen-market trades
5 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Gregory Austin Ciongoli | Director | — | $949.4K | 1 | — | |
| Steve Pakola | Chief Medical Officer | $940.0K | — | 4 | 27% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Gregory Austin Ciongoli Director | Purchase | 102,603 | $9.25 | $949.4K | 118,035 | |
traded | Steve Pakola Chief Medical Officer | SalePre-arranged (10b5-1) | 2,161 | $13.64 | $29.5K | 213,009 | |
traded | Steve Pakola Chief Medical Officer | Sale | 56,333 | $12.23 | $688.8K | 213,009 | |
traded | Steve Pakola Chief Medical Officer | SalePre-arranged (10b5-1) | 15,309 | $11.02 | $168.7K | 232,617 | |
traded | Steve Pakola Chief Medical Officer | SalePre-arranged (10b5-1) | 5,124 | $10.35 | $53.0K | 247,926 |
GET /stocks/filings/vX/form-4?tickers=RGNX&filing_date.gte=2025-11-04&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"RGNX"
],
"issuer_cik": "0001590877",
"owner_cik": "0002023732",
"accession_number": "0002023732-26-000008",
"form_type": "4",
"filing_date": "2026-08-27",
"period_of_report": "2026-08-25",
"issuer_name": "REGENXBIO Inc.",
"issuer_trading_symbol": "RGNX",
"owner_name": "Ciongoli Gregory Austin",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-26",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 49196,
"transaction_price_per_share": 9.1411,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 64628,
"transaction_value": 449705.55559999996,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $8.67 to $9.35. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."
}
]
},
{
"tickers": [
"RGNX"
],
"issuer_cik": "0001590877",
"owner_cik": "0002023732",
"accession_number": "0002023732-26-000008",
"form_type": "4",
"filing_date": "2026-08-27",
"period_of_report": "2026-08-25",
"issuer_name": "REGENXBIO Inc.",
"issuer_trading_symbol": "RGNX",
"owner_name": "Ciongoli Gregory Austin",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-27",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 53407,
"transaction_price_per_share": 9.356,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 118035,
"transaction_value": 499675.892,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F3",
"description": "Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $9.17 to $9.4525. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 36 records
- Option exercises3 records
- Tax withholding12 records
- Grants and awards21 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has REGENXBIO Inc.'s CEO sold stock?
No. Curran Simpson (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is RGNX’s insider data?
These are RGNX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track RGNX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for RGNX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.